Login to Your Account

Eyes Still on Pirfenidone in IPF

Glitch in InterMune's HCV Trial; Toxicity Worries Cut High Dose

By Jennifer Boggs

Wednesday, November 18, 2009
InterMune Inc. dipped on news that it would stop testing the highest dose in its ongoing Phase IIb study of protease inhibitor ITMN-191 in hepatitis C virus after reports of liver toxicity in three patients, offering a minor distraction for investors awaiting FDA word on the company's new drug application for fibrosis candidate pirfenidone. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription